Researchers have developed a gene therapy that upregulates Cdk1 and Cdk4 in heart muscle, promoting cardiomyocyte replication and improving function in heart failure. This therapy has shown promise in late stages of heart failure, broadening its potential impact.
Heart failure is a leading cause of mortality, and current treatments are limited. The gene therapy approach targets the proliferation of heart cells, leading to improved cardiac function and reduced scarring in chronic heart failure. The positive outcomes observed in animal models provide hope for future clinical applications.
More details about this research can be found here.
